Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Carcinoma, Renal Cell × tremelimumab × Clear all

Phase

Status

Completed 7 Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 4 Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Non-small Cell Lung Cancer 1 Pancreatic Neoplasms 1 Melanoma 1 Liver Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 5 Sunitinib 4 Sorafenib 3 Radiotherapy 3 Nivolumab 3 Interleukin-2 3 Cyclophosphamide 3 Bevacizumab 3 Axitinib 3 tivozanib 2 fludarabine phosphate 2 durvalumab 2 avelumab 2 atezolizumab 2 Radiosurgery 2 Peripheral Blood Stem Cell Transplantation 2 Optical Imaging 2 Nephrectomy 2 Magnetic Resonance Spectroscopy 2 Gene Expression Profiling 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 tremelimumab 1 temsirolimus 1 siltuximab 1 pazopanib 1 pamiparib 1 milademetan 1 fludarabine 1 bexmarilimab 1 aldesleukin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03598816 2020-08-13

PIVOT-RCC

Washington University School of Medicine

Phase 2 Withdrawn

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡